Inhibition of complement C5a prevents breakdown of the blood-brain barrier and pituitary dysfunction in experimental sepsis
Critical Care2009Vol. 13(1), pp. R12–R12
Citations Over TimeTop 10% of 2009 papers
Michael A. Flierl, Philip F. Stahel, Daniel Rittirsch, Markus Huber‐Lang, Andreas D. Niederbichler, Laszlo M. Hoesel, Basel M. Touban, Steven J. Morgan, Wade R. Smith, Peter A. Ward, Kyros Ipaktchi
Abstract
Collectively, the neutralisation of C5a greatly ameliorated pathophysiological changes associated with septic encephalopathy, implying a further rationale for the concept of pharmacological C5a inhibition in sepsis.
Related Papers
- → Evaluation of updated sepsis scoring systems and systemic inflammatory response syndrome criteria and their association with sepsis in equine neonates(2018)83 cited
- → A systematic investigation on animal models of cyclosporine A combined with Escherichia coli to simulate the immunosuppressive status of sepsis patients before onset(2018)8 cited
- → Correlation of Clinical Sepsis Definitions with Microbiological Characteristics in Patients Admitted Through a Sepsis Alert System; A Prospective Cohort Study(2021)1 cited
- → Sepsis-3-the use of sepsis in children: we still have a lot of work to do(2017)
- → Sepsis(2017)